
    
      Primary Objective:

      1. To assess 2 year probability of OS in high risk patients undergoing a myeloablative 2 step
      HSCT utilizing strategies to decrease relapse.

      Secondary Objective:

        1. To assess relapse incidence at 2 years post-HSCT of patients undergoing treatment on
           this protocol.

        2. To assess regimen related toxicity and GVHD incidence at 2 years post-HSCT and severity
           in patients undergoing treatment on this protocol.

        3. To assess the consistency and pace of engraftment.

        4. To assess the pace of T cell and B cell immune recovery.
    
  